Latest news with #PinnacleStudy
Business Wire
4 days ago
- Business
- Business Wire
Spectrum Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights
LOS ANGELES--(BUSINESS WIRE)-- The DJS Law Group reminds investors of a class action lawsuit against Spectrum Pharmaceuticals, Inc. ('Spectrum' or 'the Company') (NASDAQ: SPPI) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Shareholders who purchased shares of SPPI during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointments. Appointment as lead plaintiff is not required to partake in any recovery. CLASS PERIOD: DEADLINE: September 24, 2025 CASE DETAILS: According to the Complaint, the Company made false and misleading statements to the market. Spectrum's Pinnacle Study of poziotinib for the treatment of lung cancer was less positive than it portrayed to investors. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. If you are a shareholder who suffered a loss, contact us to participate. NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SPPI during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. There is no cost or obligation to you to participate in this case. WHY DJS LAW GROUP? DJS Law Group's primary focus is to enhance investor return through balanced counseling and aggressive advocacy. We specialize in securities class actions, corporate governance litigation, and domestic/international M&A appraisals. Our clients are some of the largest and most sophisticated hedge funds and alternative asset managers in the world. The litigation claims of our clients are extraordinarily valuable assets that demand respect, focus, and results. Join the case to recover your losses. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Malaysian Reserve
4 days ago
- Business
- Malaysian Reserve
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES, Aug. 12, 2025 /PRNewswire/ — The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ('Summit' or 'the Company') (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the 'Class Period'), are encouraged to contact the firm before September 24, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Summit misled investors about the results of its Pinnacle Study of poziotinib, a potential treatment for lung cancer patients. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Summit, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics. CONTACT: The Schall Law FirmBrian Schall, Esq., Office: 310-301-3335 info@
Business Wire
4 days ago
- Business
- Business Wire
SMMT Investors Have Opportunity to Lead Summit Therapeutics Inc. Securities Fraud Lawsuit with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Summit Therapeutics Inc. ('Summit' or 'the Company') (NASDAQ: SMMT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 17, 2022 and September 22, 2022, inclusive (the 'Class Period'), are encouraged to contact the firm before September 24, 2025. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member. According to the Complaint, the Company made false and misleading statements to the market. Summit misled investors about the results of its Pinnacle Study of poziotinib, a potential treatment for lung cancer patients. Based on these facts, the Company's public statements were false and materially misleading throughout the class period. When the market learned the truth about Summit, investors suffered damages. Join the case to recover your losses. The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
